Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ratio Therapeutics Partners with Novartis for Cancer Radiotherapy | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ratio Therapeutics Partners with Novartis for Cancer Radiotherapy

The partnership aims to develop a next-generation SSTR2-targeting therapeutic.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Ratio Therapeutics Inc., a pharmaceutical company developing radiopharmaceuticals for cancer treatment and monitoring, has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.  
 
Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments of up to $745 million and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. Novartis will assume responsibility for all remaining development, manufacturing, and commercialization activities. 
 
The collaboration leverages Ratio’s radioligand therapy discovery and development expertise as well as its technology platforms.
 
“The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.”
 
“Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximizing their impact by continually improving the benefit for patients,” said Fiona Marshall, President of Biomedical Research at Novartis. “We are delighted to collaborate with Ratio to advance this RLT candidate and work together to bring forward additional therapeutic options for patients with difficult-to-treat cancer.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics